Page last updated: 2024-12-07

hoe 694

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-methylsulfonyl-4-piperidinobenzoyl guanidine: structure given in first source; a potent inhibitor of the Na+/H+ exchanger [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123840
SCHEMBL ID9195645
MeSH IDM0200170

Synonyms (10)

Synonym
(3-methylsulphonyl-4-piperidinobenzoyl)guanidine methanesulphonate
3-methylsulfonyl-4-piperidinobenzoyl guanidine
hoe694
hoe 694
benzamide, n-(aminoiminomethyl)-3-(methylsulfonyl)-4-(1-piperidinyl)-, hydrochloride
SCHEMBL9195645
3-methylsulfonyl-4-piperidinoben-zoyl guanidine hydrochloride
n-carbamimidoyl-3-(methanesulfonyl)-4-(piperidin-1-yl)benzene-1-carboximidic acid--hydrogen chloride (1/1)
DTXSID90931253
n-(diaminomethylidene)-3-methylsulfonyl-4-piperidin-1-ylbenzamide;hydrochloride

Research Excerpts

Treatment

HOE 694-treated hearts showed significantly improved postischemic recovery of left ventricular developed pressure. Treatment with Hoe 694 prior to the ischaemic insult or upon reperfusion significantly reduced infarct size.

ExcerptReferenceRelevance
"HOE 694-treated hearts showed significantly improved postischemic recovery of left ventricular developed pressure (53.5% +/- 8.4% versus 26.4% +/- 6.6%; p = 0.036) and rate-pressure product (40.2% +/- 6.9% versus 13.2% +/- 5%; p = 0.014)."( Effects of specific sodium/hydrogen exchange inhibitor during cardioplegic arrest.
Budinger, TF; Choy, IO; DeCampli, WM; Obayashi, DY; Schepkin, VD; Young, JN, 1997
)
1.02
"Treatment with Hoe 694 before ischemia decreased histochemical infarct size from 65 +/- 18% (control group) to 13 +/- 8% (P < .01) and histological infarct size from 49 +/- 20% (control group) to 14 +/- 4% (P < .01)."( Myocardial protection by Na(+)-H+ exchange inhibition in ischemic, reperfused porcine hearts.
Bohle, RM; Klein, HH; Nebendahl, K; Pich, S; Wollenweber, J, 1995
)
0.63
"Treatment with HOE 694 prior to the ischaemic insult or upon reperfusion significantly reduced infarct size [4.1%(1.4%), P < 0.01 and 38.2%(5.8%), P < 0.05, respectively], compared with 77.7%(4.0%) in the control group."( Preischaemic as well as postischaemic application of a Na+/H+ exchange inhibitor reduces infarct size in pigs.
Minck, KO; Rohmann, S; Weygandt, H, 1995
)
0.63
"Treatment with HOE 694 leads to a significant reduction in infarct size, even when administered after the onset of ischaemia. "( Preischaemic as well as postischaemic application of a Na+/H+ exchange inhibitor reduces infarct size in pigs.
Minck, KO; Rohmann, S; Weygandt, H, 1995
)
0.64

Bioavailability

ExcerptReferenceRelevance
" The fluid absorption rate was measured after liquid application on the luminal surface of the cells."( Dexamethasone increases fluid absorption via Na+/H+ exchanger (NHE) 3 activation in normal human middle ear epithelial cells.
Choi, JY; Kim, JL; Kim, SY; Moon, UY; Shin, JH; Son, EJ; Song, MH; Yoon, JH, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves were performed for each drug."( Postcardioplegic myocardial recovery: effects of halothane, nifedipine, HOE 694, and quinacrine.
Genade, S; Lochner, A; Theron, S; Trollip, G; Tromp, E, 1998
)
0.53
" A biphasic dose-response curve for HOE-694 and N-methylisopropylamiloride (MIA) suggested that two isoforms (putatively NHE1 and NHE3) are active in the oocyte, 1-cell, and 2-cell stages."( Developmental changes in the management of acid loads during preimplantation mouse development.
Cook, DI; Day, ML; Gibb, CA; Harding, EA; Johnson, MH, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (116)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's67 (57.76)18.2507
2000's42 (36.21)29.6817
2010's7 (6.03)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.33 (24.57)
Research Supply Index4.80 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other114 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]